Pantoprazole (Pantosel 40) is chemically a novel substituted benzimidazole derivative, which suppresses the final step in gastric acid production by forming a covalent bond to two sites of the H+, K+ – ATPase enzyme system at the secretory surface of the gastric parietal cell. This leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the H+, K+ – ATPase results in duration of antisecretory effect that persists longer than 24 hours. Pantoprazole (Pantosel 40) is quantitatively absorbed and bioavailability does not change upon multiple dosing. Pantoprazole (Pantosel 40) is extensively metabolized in the liver. Almost 80% of an oral dose is excreted as metabolites in urine; the remainder is found in feces and originates from biliary secretion.
The usual recommended adult oral dose is 40 mg given once daily, before breakfast. The duration of therapy is ranging from 2-8 weeks.
Zollinger-Ellison syndrome: 4 Pantosel 40 mg tablets per day. Once control of acid secretion has been achieved, the dose should be gradually reduced to the lowest effective dose that maintains acid control.
Each box contains 10 strips of 10 tablets each.